Switch to Integrase Strand Transfer Inhibitors During the Menopausal Transition Is Associated With Accelerated Body Composition Change in Women With HIV
- 4 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (5) , 1125-1132
Abstract
Background: Integrase strand transfer inhibitors (INSTIs) and the menopausal transition have been associated with body composition changes in women with human immunodeficiency virus (WWH), but their interaction is unknown. Methods: From 2006 to 2019, 1131 virally-suppressed WWH (419 who switched to INSTI [INSTI+]; 712 who did not switch [INSTI–]) and 887 women without HIV (WWOH) from the Women's Interagency HIV Study were included. Mixed-effects models were used to evaluate change in waist circumference (WC) and body mass index (BMI) by menopausal phase defined using anti-Müllerian hormone, a biomarker of ovarian reserve. Results: During premenopause, WWH had increases in WC (INSTI+: 0.01 cm per 6 months [95% confidence interval {CI}: −.29 to .32] and INSTI−: 0.22 cm per 6 months [95% CI: −.01 to .44]) that were not statistically significantly different from WWOH; there was also little difference by INSTI status. In late perimenopause, INSTI+ had faster increases in WC (0.37 cm per 6 months [95% CI: .15–.60]) while INSTI− had smaller increases (0.14 cm per 6 months [95% CI: −.06 to .34]) compared to WWOH. In menopause, INSTI+ had faster increases, peaking at 43 months then declining, while INSTI− had smaller increases (0.14 cm per 6 months [95% CI: −.02 to .30]). Compared to INSTI−, in late perimenopause, INSTI+ had 0.26 cm per 6 months (95% CI: .02–.50) faster linear increases in WC and in menopause, INSTI+ was associated with faster increases, peaking at 41 months. Conclusions: Switching to an INSTI-based regimen during late perimenopause and menopause is associated with faster increases in WC when compared to women who did not switch. Menopausal status should be considered when switching to an INSTI.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (K24 AI 108516)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK 109823, R01 DK125246)
- National Heart, Lung, and Blood Institute (K12 HL 143961)
- National Institutes of Health
This publication has 35 references indexed in Scilit:
- Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIVAIDS Research and Human Retroviruses, 2021
- Characteristics of the MACS/WIHS Combined Cohort Study: Opportunities for Research on Aging With HIV in the Longest US Observational Study of HIVAmerican Journal of Epidemiology, 2021
- Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing RegimensClinical Infectious Diseases, 2020
- CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and EfavirenzClinical Infectious Diseases, 2020
- Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and CanadaJournal of the International AIDS Society, 2020
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIVNew England Journal of Medicine, 2019
- Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1New England Journal of Medicine, 2019
- Use of antimüllerian hormone to predict the menopausal transition in HIV-infected womenAmerican Journal of Obstetrics and Gynecology, 2017
- Comparative assessment of five serum antimüllerian hormone assays for the diagnosis of polycystic ovary syndromeFertility and Sterility, 2016
- Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trialsFertility and Sterility, 2015